INT115964

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 3.76
Pain Relevance 0.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ITGAL) cell adhesion (ITGAL) plasma membrane (ITGAL)
Anatomy Link Frequency
bladder 2
Lymphocyte 1
plaques 1
smooth muscle cells 1
ITGAL (Homo sapiens)
Pain Link Frequency Relevance Heat
fluoxetine 3 98.10 Very High Very High Very High
Desipramine 2 97.86 Very High Very High Very High
psoriasis 25 82.00 Quite High
antidepressant 6 81.92 Quite High
tolerance 4 80.44 Quite High
rheumatoid arthritis 5 67.68 Quite High
abatacept 1 66.68 Quite High
dexamethasone 2 62.28 Quite High
corticosteroid 4 59.04 Quite High
Inflammation 71 58.48 Quite High
Disease Link Frequency Relevance Heat
Adhesions 188 99.40 Very High Very High Very High
Bladder Cancer 4 98.26 Very High Very High Very High
Psoriasis 30 96.64 Very High Very High Very High
Progressive Multifocal Leukoencephalopathy 1 95.68 Very High Very High Very High
Systemic Lupus Erythematosus 56 93.20 High High
Atherosclerosis 8 91.24 High High
Viral Infection 5 85.92 High High
Nephritis 6 81.36 Quite High
Stress 9 81.12 Quite High
Congenital Anomalies 4 80.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Efalizumab inhibits T-cell activation, cutaneous trafficking, and adhesion to keratinocytes through the blockade of LFA-1/ICAM-1 binding, steps in the immunologic cascade that lead to the formation of the psoriatic plaques (Menter et al 2005).
Negative_regulation (blockade) of LFA-1 in plaques associated with psoriasis and adhesions
1) Confidence 0.34 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727906 Disease Relevance 0.73 Pain Relevance 0.07
Efalizumab, an LFA-1 inhibitor (Lymphocyte function associated Antigen-1), was withdrawn from the market in 2010 because of concerns with progressive multifocal leukoencephalopathy, and its cutaneous SLE trial was suspended.
Negative_regulation (inhibitor) of LFA-1 in Lymphocyte associated with progressive multifocal leukoencephalopathy and systemic lupus erythematosus
2) Confidence 0.16 Published 2010 Journal BMC Med Section Body Doc Link PMC3009611 Disease Relevance 0.73 Pain Relevance 0.17
Young et al. [187] purified sICAM-1 from normal human serum and the urine of patients with bladder cancer by immunoaffinity chromatography and detected only monomeric sICAM-1, which could not block LFA-1/ICAM-1-dependent cell-mediated cytolosis of bladder tumour target cells.
Negative_regulation (block) of LFA-1 in bladder associated with bladder cancer
3) Confidence 0.11 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 0.31 Pain Relevance 0.03
Young et al. [187] purified sICAM-1 from normal human serum and the urine of patients with bladder cancer by immunoaffinity chromatography and detected only monomeric sICAM-1, which could not block LFA-1/ICAM-1-dependent cell-mediated cytolosis of bladder tumour target cells.
Negative_regulation (block) of LFA-1 in bladder associated with bladder cancer
4) Confidence 0.11 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 0.31 Pain Relevance 0.03
Chen et al conducted a transient transfection experiment in rat aortic smooth muscle cells to show that longer (GT)n repeats in HO-1 promoter decreased luciferase promoter activity, indicating decrease in gene transcription in vascular cells[24].
Negative_regulation (decreased) of luciferase promoter in smooth muscle cells
5) Confidence 0.04 Published 2010 Journal J Biomed Sci Section Body Doc Link PMC2841098 Disease Relevance 1.15 Pain Relevance 0
It was found that imipramine, amitryptyline, desipramine, fluoxetine, and mianserin, present in the culture medium for 5 days, in a concentration-dependent manner inhibited basal hCRH gene promoter activity in undifferentiated Neuro-2A cells, while other drugs under study (citalopram, tianeptine, moclobemide, venlafaxine, reboxetine, mirtazapine, and milnacipram) were inactive.
Negative_regulation (inhibited) of hCRH gene promoter associated with desipramine and fluoxetine
6) Confidence 0.02 Published 2004 Journal Neuropsychopharmacology Section Abstract Doc Link 14735130 Disease Relevance 0.11 Pain Relevance 0.47
Silencing NFkB, IRF3 and IRF7 but not VISA (Figure 6B) decreased expression of ISG15 probably due to the decreased activity of ISRE promoter as also monitored by the decreased production of reporter gene in transfected cells at least for IRF7 (Figure 6C).
Negative_regulation (decreased) of ISRE promoter
7) Confidence 0.01 Published 2010 Journal J Transl Med Section Body Doc Link PMC2845551 Disease Relevance 0.42 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox